NASDAQ:XDNA Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News $7.38 0.00 (0.00%) As of 08/29/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsOptions ChainTrendsBuy This Stock About Kelly CRISPR & Gene Editing Technology ETF (NASDAQ:XDNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XDNA alerts:Sign Up Key Stats Today's Range$7.38▼$7.3850-Day Range$7.38▼$7.3852-Week Range$5.87▼$11.83VolumeN/AAverage Volume3,034 shsMarket Capitalization$2.21 millionAssets Under Management$2.58 millionDividend Yield0.12%Net Expense Ratio0.78%Aggregate RatingN/A ETF Overview The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly. Read More Kelly CRISPR & Gene Editing Technology ETF ExpensesTypeXDNATheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.78%0.57%0.56%0.54%0.53%Other Expenses0.00%0.57%0.56%0.52%0.56%Total Expense0.78%0.74%0.76%0.73%0.73%Fee Waiver0.00%-0.76%-0.66%-0.50%-0.63%Net Expense0.78%0.60%0.63%0.63%0.60% Receive XDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kelly CRISPR & Gene Editing Technology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XDNA ETF News HeadlinesCHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare diseaseMay 15, 2025 | msn.comNobel Prize winners convince court to revive CRISPR patent disputeMay 12, 2025 | reuters.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 30 at 2:00 AM | Banyan Hill Publishing (Ad)Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right nowOctober 2, 2024 | yahoo.comK-12 Genome Editing at Only $2 a PopSeptember 27, 2024 | yahoo.comVertex Stock: Came For CF Drugs, Staying For Gene TherapyAugust 2, 2024 | seekingalpha.comSee More Headlines XDNA ETF - Frequently Asked Questions How have XDNA shares performed this year? Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 on January 1st, 2025. Since then, XDNA shares have increased by 0.0% and is now trading at $7.38. How do I buy shares of Kelly CRISPR & Gene Editing Technology ETF? Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kelly CRISPR & Gene Editing Technology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kelly CRISPR & Gene Editing Technology ETF investors own include Meta Platforms (META), RTX (RTX), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Cloudflare (NET), Birkenstock (BIRK) and Baidu (BIDU). Fund Details IssuerKelly Strategic Management Fund NameKelly CRISPR & Gene Editing Technology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:XDNA Inception Date1/12/2022 Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkStrategic CRISPR & Gene Editing Technology Index CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings2 Fund Statistics Assets Under Management$2.58 million Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorKelly Strategic Management, LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerJane Street Miscellaneous Outstanding Shares300,000Beta0.92 Creation Unit25,000 Creation Fee$250.00 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Top 3 XDNA HoldingsFirst American Government Obligations FundHolding Weight: 49.96%First American Treasury Obligations FundHolding Weight: 49.96%DEPOSITS WITH BROKER FOR SHORT POSITIONSHolding Weight: 0.09%Full Holdings Details This page (NASDAQ:XDNA) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Kelly CRISPR & Gene Editing Technology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
